share_log

Cantor Fitzgerald Maintains Overweight on SELLAS Life Sciences Gr, Lowers Price Target to $6

Benzinga Real-time News ·  Jun 28, 2022 08:44

Cantor Fitzgerald analyst Li Watsek maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and lowers the price target from $10 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment